ImageneBio (IMA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$10.2M

Net income growth (year over year)

−34.19%

Net margin

—

Return on equity

−41.34%

EPS (trailing twelve months)

−$2.90

Book value per share

$12.60

P/E (trailing twelve months)

—

Price to book

0.33

Debt to assets

6.56%

Payout ratio

—

Dividend yield

—

Company profile

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

• How do I buy stock in ImageneBio (IMA)?

  IMA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.